How an acquisition has quadrupled production for Seqirus in Holly Springs
Two years out from parent company CSL ’s acquisition of the global influenza vaccine business of Novartis for $275 million, Seqirus continues to ramp up production at its Holly Springs site.
Source: bizjournals.com Health Care:Biotechnology headlines - Category: Biotechnology Authors: Jennifer Henderson Source Type: news
More News: Biotechnology | Health Management | Influenza | Influenza Vaccine | Mergers and Aquisitions | Vaccines